European Archives - Page 1038 of 1469 - European Medical Journal

EMJ Hematology US 1.1 2020

EMJ Hematology US 1.1 2020

EMJ Hematology US Edition is the newest addition to our haematology collection, and contains a review of ASH 2019, interviews with leading members of ASH…

EMJ Presents: EMJ Hematology US 2020

Today we release our first ever EMJ Hematology US Edition Journal, presenting the latest breakthroughs within the field along with our exclusive coverage…

EMJ Hematology US 1.1 2020

Acute Chest Syndrome in Children with Sickle Cell Disease: Current Perspectives

Acute chest syndrome (ACS) is an acute inflammatory lung injury that usually follows the vaso-occlusive crisis (VOC) seen in sickle cell disease (SCD)…

EMJ Hematology US 1.1 2020

Fli-1 Transcriptionally Integrates Microenvironmental Cues Sensing by Self-Renewing Haematopoietic Stem and Progenitor Cells

During adulthood and embryogenesis, fate decisions of haematopoietic stem and progenitor cells (HSPC), such as specification, self-renewal, and…

Review of the American Society of Hematology (ASH) Congress 2019

The City Beautiful” proved to be an appropriate nickname for Orlando, Florida, USA, where the sun shined as >30,000 attendees flocked to attend this…

Dr Emanuele Angelucci

Chair, Hematology and Cellular Therapy Unit, Ospedale Policlinico San Martino; Transplant Program Director, Istituto di Ricovero e Cura a…

EMJ

Dr Dimitar Efremov

ASH 2019 Interviews

We spoke to Prof Theresa L. Coetzer, the Chair of the ASH International Members Committee, and Dr Pierluigi Porcu, the Chair of ASH Foundation…

EMJ Hematology US 1.1 2020

Novel CD33 Antibodies Reveal CD33 Splicing Polymorphism Variant Localisation and Therapeutic Implications

Acute myeloid leukaemia (AML) is a heterogeneous haematologic malignancy characterised by dysfunctional proliferation and differentiation of myeloid progenitor cells.

EMJ Hematology US 1.1 2020

Therapeutic Options in Myelodysplastic Syndromes Following Hypomethylating Agent Failure

Myelodysplastic syndromes (mds) are a heterogeneous group of disorders defined by ineffective haematopoiesis and clonal instability with risk of…